**Author details**

Gianfranco Lapietra, Francesca Fazio and Maria Teresa Petrucci\* Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy

\*Address all correspondence to: petrucci@bce.uniroma1.it

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**79**

*The Modern Age of Monoclonal Antibodies: The Revolution of Daratumumab*

with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet.

[10] Usmani SZ, Nahi H, Mateos MV, et al. Subcutaneous delivery of daratumumab in relapsed or

refractory multiple myeloma. Blood.

[11] Mateos MV, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed

or refractory multiple myeloma (COLUMBA): a multicentre, openlabel, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020

[12] Usmani SZ, Weiss BM, Plensrer T, et al. Clinical efficacy of daratumumab

[13] Gandhi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiaolos via modulation of the E3 ubiquitin ligase complex CRL4 (CRBN). Br J Haematol. 2014;164(6):811-821.

[14] van der Veer MS, de Weers M, van Kessel B, et al. The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood

[15] Plesner T, Arkenau H-T, Gimsing P, et al. Phase ½ study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood.

[16] Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and

Cancer J. 2011; 1(10):e41.

2016; 128(14).1821-1828.

monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood.

2016;387:1551-1560.

2019;134(8):668-677.

May;7(5):e370-e380.

2016;128(1):37-44.

*DOI: http://dx.doi.org/10.5772/intechopen.95406*

[2] Cagnetta A, Cea M, Calimeri T, et al.

Antonioli L, et al. Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche. Front

Mitochondrial Trafficking Promotes Bioenergetic Plasticity in Multiple Myeloma. Cancer Res. 2019 May

[5] van de Donk NWCJ, Usmani SZ. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance. Front Immunol. 2018 Sep

[6] van de Donk NW, Janmaat ML, Mutis T, et al. Monoclonal antibodies targeting CD38 in hematological

malignancies and beyond. Immunol Rev.

[7] Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune

regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128

[8] Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med.

[9] Lonial S, Weiss B, Usmani S, et al. Daratumumab monotherapy in patients

2015;373:1207-1219.

bortezomib-induced anti-myeloma activity. Blood. 2013; 122(7):1243-1255.

[3] Chillemi A, Quarona V,

[4] Marlein CR, Piddock RE, Mistry JJ, et al. CD38-Driven

Immunol. 2017; 8:305.

1;79(9):2285-2297.

20; 9:2134.

2016; 270:95-112.

(3):384-394.

depletion enhances

[1] Morandi F, Horenstein AL, Costa F et al. CD38: a target for immunotherapeutic approaches in multiple myeloma. Front Immunol.

**References**

2018; 9: 2722.

Intracellular NAD+

*The Modern Age of Monoclonal Antibodies: The Revolution of Daratumumab DOI: http://dx.doi.org/10.5772/intechopen.95406*
